Apollomics Inc. Warrant closed at $0.01 on Sep 28, unchanged, 61.3% below its highest close since Mar 30. Volume of 6.2K shares was 0.52× its 20-day average (below normal).
Split-adjusted performance: -18.9% over one month, -28.0% over six months.
Short interest was 44.8K shares at the Sep 15 settlement, up 27.6% from the prior report (4.7 days to cover).
No recent articles focused on Apollomics Inc. Warrant.
Quick answers
What does Apollomics Inc. Warrant do?
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
What is APLMW's market cap?
$1.04M, based on the Sep 28 close of $0.01.
About Apollomics Inc. Warrant
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
